HIV-1 inhibitor-6
Based on 1 publication(s) in Google Scholar
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50s ranging from 0.9 to 1.5 μM.
For research use only. We do not sell to patients.
- Purity: 99.10%
- CAS No.: 1821309-39-0
- Formula: C14H10N4O4S
- Molecular Weight:330.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Antiviral Compound Library
HY-L027
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) HIV-1 inhibitor-6
More
Biological Activity
|
X4 HIV-1 (IIIB) 0.6 μM (EC50) |
R5 HIV-1 0.9 μM (EC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | CC50 |
>100 μM
Compound: 9; 1C8
|
Cytotoxicity against GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 assessed as cell viability at after 24 hrs by Guava viacount assay
Cytotoxicity against GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 assessed as cell viability at after 24 hrs by Guava viacount assay
|
[PMID: 26878150] |
| CCRF-CEM | EC50 |
0.6 μM
Compound: 9; 1C8
|
Antiviral activity against subtype B X4 tropic HIV1 3B infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
Antiviral activity against subtype B X4 tropic HIV1 3B infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
|
[PMID: 26878150] |
| CCRF-CEM | EC50 |
0.9 μM
Compound: 9; 1C8
|
Antiviral activity against maraviroc-resistant HIV1 BAL R5 harboring envelop V3 A19T/L20F/T22A/E25D/126V mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
Antiviral activity against maraviroc-resistant HIV1 BAL R5 harboring envelop V3 A19T/L20F/T22A/E25D/126V mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
|
[PMID: 26878150] |
| CCRF-CEM | EC50 |
0.9 μM
Compound: 9; 1C8
|
Antiviral activity against subtype A R5 tropic HIV1 97USSN54 infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
Antiviral activity against subtype A R5 tropic HIV1 97USSN54 infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
|
[PMID: 26878150] |
| CCRF-CEM | EC50 |
1.3 μM
Compound: 9; 1C8
|
Antiviral activity against NNRTI-resistance HIV1 E00443 harboring reverse transcriptase D67N/K70R/Y115F/Q151M/M184V/K219Q mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
Antiviral activity against NNRTI-resistance HIV1 E00443 harboring reverse transcriptase D67N/K70R/Y115F/Q151M/M184V/K219Q mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
|
[PMID: 26878150] |
| CCRF-CEM | EC50 |
1.4 μM
Compound: 9; 1C8
|
Antiviral activity against PI-resistant HIV1 isolate 2948 harboring protease G48V/L90M mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
Antiviral activity against PI-resistant HIV1 isolate 2948 harboring protease G48V/L90M mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
|
[PMID: 26878150] |
| CCRF-CEM | EC50 |
1.5 μM
Compound: 9; 1C8
|
Antiviral activity against INI-resistant HIV1 isolate 11845 harboring integrase G140S/Q148H mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
Antiviral activity against INI-resistant HIV1 isolate 11845 harboring integrase G140S/Q148H mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days
|
[PMID: 26878150] |
Chemical Information
-
CAS No. 1821309-39-0
-
Appearance Solid
-
Molecular Weight 330.32
-
Formula C14H10N4O4S
-
Color Yellow to orange
-
SMILES
O=C(C1=CN(C)C=CC1=O)NC2=NSC3=C2C=C([N+]([O-])=O)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Commun (Lond)
Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. [Abstract]2024 Nov;44(11):1231-1260. PMID: 39223929
Solvent & Solubility
DMSO : 3.33 mg/mL (10.08 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0274 mL | 15.1368 mL | 30.2737 mL | 75.6842 mL |
| 5 mM | 0.6055 mL | 3.0274 mL | 6.0547 mL | 15.1368 mL | |
| 10 mM | 0.3027 mL | 1.5137 mL | 3.0274 mL | 7.5684 mL |
HIV-1 inhibitor-6 Related Classifications
HY-134851 Related Classifications
Powered by Bioz